Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: Secondary and post-hoc analyses

The Lancet Neurology

Volumn 14, Issue 12, 2015, Pages 1171-1181

  Howard, Robert ^a,b   McShane, Rupert ^c   Lindesay, James ^d   Ritchie, Craig ^e   Baldwin, Ashley ^f   Barber, Robert ^g   Burns, Alistair ^h   Dening, Tom ⁱ   Findlay, David ^j   Holmes, Clive ^k   Jones, Robert ⁱ   Jones, Roy ^l   McKeith, Ian ^m   Macharouthu, Ajay ⁿ   O'Brien, John ^o   Sheehan, Bart ^p   Juszczak, Edmund ^q   Katona, Cornelius ^a   Hills, Robert ^r   Knapp, Martin ^s   Ballard, Clive ^b   Brown, Richard G ^b   Banerjee, Sube ^t   Adams, Jessica ^b   Johnson, Tony ^a   Bentham, Peter ^u   Phillips, Patrick P J ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c WARNEFORD HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f 5 Boroughs Partnership NHS Trust   (United Kingdom)

^g Newcastle upon Tyne   (United Kingdom)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^j Kingsway Care Centre   (United Kingdom)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^l Research Institute for the Care of Older People   (United Kingdom)

^m NEWCASTLE UNIVERSITY   (United Kingdom)

ⁿ CROSSHOUSE HOSPITAL   (United Kingdom)

^o UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^p OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^q UNIVERSITY OF OXFORD   (United Kingdom)

^r CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^s LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^t UNIVERSITY OF SUSSEX   (United Kingdom)

^u BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NURSING HOME; PHYSICIAN; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; TREATMENT DURATION; UNITED KINGDOM; COGNITION; DRUG EFFECTS; HOME FOR THE AGED; NEUROPSYCHOLOGICAL TEST; NURSING; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HOMES FOR THE AGED; HUMANS; INDANS; MALE; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; NURSING HOMES; PIPERIDINES; SEVERITY OF ILLNESS INDEX;

EID: 84946723479     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00258-6     Document Type: Article

References (32)

1. Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002, 287:2090-2097.
2. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004, 363:2105-2115. for the AD2000 Collaborative Group.
3. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology 1996, 47:166-177.
4. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003, 51:937-944.
5. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002, 72:310-314.
6. Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005, 53:83-87.
7. Feldman HH, Pirttila T, Dartigues JF, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 2009, 24:479-488.
8. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2009, 80:600-607.
9. Finucane TE Another advertisement for donepezil. J Am Geriatr Soc 2004, 52:843.
10. Royall DR Donepezil's effects remain uncertain. J Am Geriatr Soc 2004, 52:843-845.
11. Karlawish JH Donepezil delay to nursing home placement study is flawed. J Am Geriatr Soc 2004, 52:845.
12. Schneider LS, Qizilbash N Delay in nursing home placement with donepezil. J Am Geriatr Soc 2004, 52:1024-1026.
13. Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess 2012, 16:1-470.
14. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012, 366:893-903.
15. Jones R, Sheehan B, Philips P, et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's Disease-a multicentre RCT. Trials 2009, 10:57. for the DOMINO-AD team.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRADA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
17. Molloy DW, Standish TI A guide to the standardised Mini-Mental State Examination. Int Psychogeriatr 1997, 9(suppl 1):87-94.
18. McEntegart DJ The pursuit of balance using stratified and dynamic randomization techniques: an overview. Drug Inf J 2003, 37:293-308.
19. Beecham J, Knapp M Costing psychiatric interventions. Measuring mental health needs 2001, 200-224. Gaskell, London. 2nd edn. G. Thornicroft (Ed.).
20. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996, 25:113-120.
21. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381:805-816. for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
22. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
24. Smith SC, Lamping DL, Banerjee S, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument and an evaluation of current methodology. Health Technol Assess 2005, 9:1-93.
25. Royston P, Lambert PC Flexible parametric survival analysis using stata: beyond the Cox model 2011, Stata Press, College Station.
26. Hernan MA The hazards of hazard ratios. Epidemiology 2010, 21:13-15.
27. Royston P, Parmar MK Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 2013, 13:152.
28. Folstein MF, Folstein SE, McHugh PR "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
29. Hatoum HT, Thomas SK, Lin SJ, Lane R, Bullock R Predicting time to nursing home placement based on activities of daily living score-a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil. J Med Econ 2009, 12:98-103.
30. Schneider LS Discontinuing donepezil or starting memantine for Alzheimer's disease. N Engl J Med 2012, 366:957-959.
31. Knapp M, Comas-Herrera C, Wittenberg R, et al. Scenarios of dementia care: what are the impacts on cost and quality of life? 2014, Personal Social Services Research Unit, London.
32. Karlawish JH, Klocinski JL, Merz J, Clark CM, Asch DA Caregivers' preferences for the treatment of patients with Alzheimer's disease. Neurology 2000, 55:1008-1014.